Kadmon is a biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology, and genetic diseases. 

Employee Rating

1.8More
TypePublic
HQNew York, US
Founded2010
Size (employees)103 (est)+3%
Websitekadmon.com
Kadmon was founded in 2010 and is headquartered in New York, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Kadmon

Harlan Waksal

Harlan Waksal

President and Chief Executive Officer
Steven Gordon

Steven Gordon

Executive Vice President, General Counsel, Chief Administrative, Compliance and Legal Officer
John Ryan

John Ryan

Executive Vice President, Chief Medical Officer
Show more

Kadmon Office Locations

Kadmon has an office in New York
New York, US (HQ)
450 E 29th St
Show all (1)
Report incorrect company information

Kadmon Financials and Metrics

Kadmon Revenue

Embed Graph
View revenue for all periods
Kadmon's revenue was reported to be $12.26 m in FY, 2017
USD

Revenue (Q3, 2018)

372.0k

Gross profit (Q3, 2018)

313.0k

Gross profit margin (Q3, 2018), %

84.1%

Net income (Q3, 2018)

(13.8m)

EBIT (Q3, 2018)

(21.3m)

Market capitalization (14-Dec-2018)

279.4m

Closing stock price (14-Dec-2018)

2.5

Cash (30-Sep-2018)

113.4m
Kadmon's current market capitalization is $279.4 m.
Annual
USDFY, 2016FY, 2017

Revenue

26.1m12.3m

Cost of goods sold

3.5m1.3m

Gross profit

22.6m10.9m

Gross profit Margin, %

87%89%
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

6.4m5.7m5.6m3.0m2.3m433.0k359.0k372.0k

Cost of goods sold

880.0k880.0k567.0k266.0k277.0k199.0k103.0k59.0k

Gross profit

5.5m4.8m5.0m2.7m2.0m234.0k256.0k313.0k

Gross profit Margin, %

86%85%90%91%88%54%71%84%
Annual
USDFY, 2016FY, 2017

Cash

36.1m67.5m

Accounts Receivable

655.0k325.0k

Inventories

2.0m201.0k

Current Assets

40.3m70.0m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

5.5m55.0m43.0m26.2m73.6m49.2m131.5m113.4m

Accounts Receivable

640.0k1.1m1.3m1.0m222.0k537.0k534.0k972.0k

Inventories

2.7m2.3m1.6m1.1m212.0k466.0k665.0k1.1m

Current Assets

13.2m59.9m48.6m31.1m76.5m51.7m134.3m117.6m
Annual
USDFY, 2016FY, 2017

Net Income

(208.8m)(79.8m)

Inventories

1.1m95.0k

Accounts Payable

530.0k1.6m

Cash From Operating Activities

(52.9m)(64.1m)
Quarterly
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Kadmon News and Updates

Kadmon Provides Business Update and Reports Third Quarter 2018 Financial Results

NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the third quarter of 2018.

Kadmon to Present at the Jefferies 2018 London Healthcare Conference

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14 at 8:40 a.m. GMT (3:40 a.m. ET).

Kadmon Presents New Preclinical Data on its Immuno-Oncology Fusion Protein at SITC Annual Meeting

NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced it will present preclinical data on KD033, its anti-PD-L1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place Nove…

Kadmon Announces Oral Presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting

NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that updated data from its ongoing Phase 2 clinical trial evaluating KD025 for the treatment of chronic graft-versus-host disease (cGVHD) have been selected for oral presentation at the 60th American Soc…
Report incorrect company information

Kadmon Company Life and Culture

Report incorrect company information

Kadmon Frequently Asked Questions

  • When was Kadmon founded?

    Kadmon was founded in 2010.

  • Who are Kadmon key executives?

    Kadmon's key executives are Harlan Waksal, Steven Gordon and John Ryan.

  • How many employees does Kadmon have?

    Kadmon has 103 employees.

  • What is Kadmon revenue?

    Latest Kadmon annual revenue is $12.3 m.

  • What is Kadmon revenue per employee?

    Latest Kadmon revenue per employee is $119.1 k.

  • Who are Kadmon competitors?

    Competitors of Kadmon include MyoKardia, Athersys and Otonomy.

  • Where is Kadmon headquarters?

    Kadmon headquarters is located at 450 E 29th St, New York.

  • Where are Kadmon offices?

    Kadmon has an office in New York.

  • How many offices does Kadmon have?

    Kadmon has 1 office.